ROME Therapeutics logo

ROME Therapeutics

Recent Finacing

Series B

Recent Raise

$72M


ROME Therapeutics is a biotechnology company that develops breakthrough medicines for serious diseases, with a focus on an inhibitor of LINE-1 reverse transcriptase for autoimmune diseases, using their proprietary data science platform to identify active repeat elements and assess their roles in disease.

Total Funding

$72M

Headquarters

Boston, USA

Founded

N/A

Website

Focus Areas

Biotechnology
Autoimmune Diseases
Drug Discovery

Investors